ClinicalTrials.gg
RecruitingNCT03739827Updated Nov 20, 2026

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

An observational study in Malignant Solid Tumors, Other Neoplasms Solid Tumors and Pediatric Solid Tumor, sponsored by National Cancer Institute (NCI). Recruiting at 3 sites in United States. Open to participants aged 4 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Cancer Institute (NCI) · Observational

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
4 Weeks and older
Sex
All
01

Study summary

Background:

Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order to learn more about how these tumors develop. The information obtained from this study may lead to improved screening, preventive guidelines, and treatments.

Objective:

To better understand rare cancers and hereditary cancer syndromes.

Eligibility:

People who have a rare tumor, a family history of a rare tumor, a hereditary cancer syndrome, or a mutation that leads to rare tumors.

Design:

Participants will be screened with questions about their medical history and/or that of their family members. They will give a saliva sample.

Participants who have a tumor will have their medical records and tests reviewed. They will answer questions about their wellbeing and needs. They may provide a tumor tissue sample.

Participants may also have:

  • Physical exam
  • Clinical photography
  • Blood, urine, saliva, and stool samples taken
  • Consultation with specialists
  • A scan that produces a picture of the body. Either one that uses a small amount of radiation, or one that uses a magnetic field.
  • Genetic testing/genetic counseling.

Participants will be contacted once a year. They will answer updated questions about their medical and family history.

Participants will be asked to contact the study team if there are changes in their tumors.

Participants may be invited to join focus groups for people with the same diagnosis of rare tumors.

Participants may be invited to participate in other NIH protocols.

****************************************

****************************************

RARE TUMOR LIST:

  1. Acinar cell carcinoma of the pancreas
  2. Adamantinoma
  3. Adenosqaumous carcinoma of the pancreas
  4. Adrenocortical carcinoma
  5. Alveolar soft part sarcoma
  6. Anaplastic Thyroid Cancer
  7. Angiosarcoma
  8. Atypical Teratoid Rhabdoid Tumor/MRT
  9. Carcinoid
  10. Carcinoma of Unknown Primary
  11. Chondrosarcoma
  12. Chondromyxoid fibroma
  13. Chordoma
  14. Clear cell renal carcinoma
  15. Clear Cell Sarcoma
  16. Clear cell sarcoma of kidney
  17. Conventional chordoma
  18. Dedifferentiated chordoma
  19. Desmoid
  20. Desmoplastic small round cell tumor
  21. Epithelioid hemangioendothelioma
  22. Esthenioneuroblastoma
  23. Ewing Sarcoma
  24. Fibrolamellar carcinoma
  25. Fusion negative rhabdomyosarcoma
  26. Fusion positive renal cell carcinoma
  27. Fusion positive rhabdomyosarcoma
  28. Gastro-enteropancreatic neuroendocrine tumor
  29. Hepatoblastoma
  30. Hereditary Diffuse Gastric Cancer
  31. Inflammatory myofibroblastic tumor
  32. Kaposiform hemangioendothelioma
  33. Malignant ectomesenchymal tumor
  34. Malignant peripheral nerve sheath tumor
  35. Malignant triton tumor
  36. Medullary thyroid cancer
  37. Mixed acinar adenocarcinoma
  38. Mixed acinar neuroendocrine carcinoma
  39. Myxoid Liposarcoma
  40. Neuroblastoma
  41. Neuroendocrine tumors
  42. NUT midline carcinoma
  43. Osteosarcoma
  44. Pancreas ductal adenocarcinoma with squamous features
  45. Pancreatic acinar cell carcinoma
  46. Papillary renal cell carcinoma
  47. Paraganglioma
  48. Parosteal Osteosarcoma
  49. Periosteal Osteosarcoma
  50. Peripheral nerve sheath tumor
  51. Peripheral primitive neuroectodermal tumor
  52. Pheochromocytoma
  53. Pituitary cancer
  54. Poorly differentiated chordoma
  55. Renal medullary carcinoma
  56. Rhabdomyosarcoma
  57. Round cell Liposarcoma
  58. Schwannoma
  59. Sclerosing Epithelioid Fibrosarcoma
  60. SDH deficient GIST
  61. SMARCB1 deficient tumors
  62. SMARCA4 deficient tumors
  63. Synovial sarcoma
  64. Undifferentiated Sarcoma

    ****************************************

    ****************************************

Read the detailed description

Background:

Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgkin lymphoma, and kidney/renal pelvis neoplasms) and will not be studied in this trial. One-quarter of all adults with tumor have a rare tumor diagnosis.

All pediatric tumors meet this definition of rare affecting \< 1% individuals younger than 20 years per year in the US.

Notably, there is a group of solid tumors that occur so infrequently in children and adults that little is known about the natural history of these tumors, their clinical behavior, molecular/genetic characteristics, optimal management, and drug response.

The NCI and the NIH Clinical Center infrastructure are uniquely suited to conduct studies of rare tumors. There is a precedent in the NCI when even non-interventional studies or initiatives were paradigm-changing. The NCI neurofibromatosis type 1 natural history study allowed the development of groundbreaking interventional trials in participants with plexiform neurofibromas. The Pediatric and Wild-Type Gastrointestinal Stromal Tumor (GIST) Clinic, which involves intramural and extramural experts, not only provided the background for discovery of the molecular features of a very rare disease such as succinate dehydrogenase deficient GIST, but also was able identify therapeutic strategies for this group of participants (for example, avoidance of unnecessarily aggressive surgery). Similarly, studies in adults at the CCR have tremendously advanced the understanding of rare solid tumors occurring primarily in adults such as thymoma, renal cell cancer, and endocrine tumors.

Systematic and longitudinal collection and annotation of clinical history, tissue samples, imaging studies, patient reported outcomes, and other pertinent information in participants with these rare tumors and return of results to participants will provide a service to the participants themselves and to the medical community, in line with the NIH mission of to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability .

Objective:

To comprehensively and longitudinally evaluate the natural history of participants with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival).

Eligibility:

Participants with a diagnosis of a rare solid tumor (fewer than 15 cases in 100,000 people per year).

OR

Relatives of participants with diagnosis of rare solid tumors

OR

Carriers of germline genetic variants that predispose to rare solid tumor and their relatives.

Design:

This will be a long-term study to comprehensively study participants (and their relatives) with select rare tumors.

Initially participants will provide clinical information (medical history, family medical history, imaging studies and reports, surgical pathology reports, genetic test results, patient-reported outcomes) and biospecimens (archival pathology specimen and saliva) for review by and feedback from the study team.

If indicated, participants will be invited to the study site for additional evaluations and consultation, including clinical phenotyping, genotyping, imaging of tumor sites, and patient reported or other appropriate outcomes.

After evaluation, participants will be provided with recommendations about possible treatment options and might be enrolled into disease specific sub-protocols of this trial.

Since long-term follow-up of individuals with rare tumors, their family members at high risk for developing tumors, and carriers of germline genetic variants is a major feature of the study, we intend to maintain active contact with study subjects for as long as possible.

In addition to evaluating individual participants, this protocol will allow bringing groups of participants (approximately 10-20) with specific rare tumors for a rare tumor clinic on the same day to allow for development of a deeper understanding of rare tumors through the conduct of focus groups.

02

Conditions studied

  • Malignant Solid Tumors
  • Other Neoplasms Solid Tumors
  • Pediatric Solid Tumor
  • Refractory Solid Tumors
  • Solid Tumor

Keywords

  • Service to the Patients
  • Knowledge about the Nature of Cancer
  • Cancer Evaluations
  • Natural History
03

In context

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Weeks and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Primary clinical

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1: Participants with a diagnosis of a rare solid tumor (fewer than 15 cases in 100,000 people per year). There are no age restrictions beyond the neonatal period (4 weeks).

OR

-Cohort 2: Participants without a rare tumor who have a germline genetic variant that predisposes to a rare solid tumor

OR

-Cohort 3: Relatives of participants with diagnosis of rare solid tumors who do NOT have a known germline variant that predisposes to a rare solid tumor

OR

  • Cohort 4: Parent/guardian of child participating in a focus group if not already enrolled on the study.
  • Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written document.

Exclusion criteria

EXCLUSION CRITERIA:

None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)

Groups and cohorts

  • 1/Cohort 1

    Subjects with a diagnosis of rare tumor (fewer than 15 cases in 100,000 people per year)

  • 2/Cohort 2

    Relatives of subjects with a rare tumor who have a germline genetic variant that predispose to a rare solid tumor or a subject who has a germline genetic variant that predispose to a rare solid tumor

  • 3/Cohort 3

    Relatives of subjects with a diagnosis of rare tumor that do NOT have known germline genetic variants that predispose to a rare solid tumor.

  • 4/ Cohort 4

    Parents/guardians of children with a diagnosis of rare tumor participating in focus groups (if not enrolled in Cohorts 1, 2 or 3)

06

What researchers measure

Primary outcomes

  1. To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival)

    To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival)

    Time frame: 10 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.

Access criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.

09

Timeline

7 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2019 (actual). Primary completion is estimated for May 2028, 112 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2018
First posted
Nov 14, 2018
StartActual
Jan 28, 2019
Primary completionEst.
May 31, 2028
CompletionEst.
Mar 31, 2032
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
7 updates, last Nov 20, 2026
Show all 7 updates
  1. Nov 20, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  3. Oct 29, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 16, 2026
    Minor edits only
    + 2 other changes: verification date and description
  6. Oct 13, 2026
    Minor edits only
    + 1 other change: description
  7. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03739827
Responsible party
Sponsor
First posted
Nov 14, 2018
Start date
Jan 28, 2019
Primary completion
May 31, 2028 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Nov 20, 2026

Study contacts

Barbara J Thomas, R.N.
Contact
barbara.thomas2@nih.gov
(240) 858-3633
Mary F Wedekind Malone, D.O.
Contact
maryfrances.wedekindmalone@nih.gov
(240) 858-3765
Mary F Wedekind Malone, D.O.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion